Table 1.
Correlations of the main clinical, radiological, and laboratory characteristics of the 65 bronchiectasis patients with inhaled corticosteroids.
| Correlation with ICS Use | ||||
|---|---|---|---|---|
| Without ICS Use (n = 28) | With ICS Use (n = 37) | Spearman ρ (CI) | p | |
| Male, n (%) | 16 (53.3) | 14 (46.6) | 0.08 (−0.22, 0.33) | 0.90 |
| Age at referral, years, n (%) | 7.5 (2.7) | 7.7 (2.8) | 0.04 (−0.19, 0.29) | 0.86 |
| SPT, n (%) | 28 (100) | 37 (100) | ||
| ‒ Positive SPT, n (%) | 1 (2.7) | 15 (53.6) | 0.55 (0.36, 0.70) | <0.001 |
| Serum IgE, IU/mL, mean (sd) | 49.8 (47.7) | 72.1 (69.4) | 0.25 (−0.03, 0.45) | 0.16 |
| Blood eosinophil count, mean (sd) | 260 (225) | 361 (322) | 0.26 (0.01, 0.40) | 0.20 |
| T2-high status, n (%) | 3 (8.1) | 3 (10.7) | 0.04 (−0.09–0.39) | 0.72 |
| Spirometry, n (%) | 22 (48.9) | 23 (51.1) | ||
| ‒ ppFEV1, mean (sd) | 94.2 (13.5) | 88.5 (12.1) | −0.41 (−0.63, −0.14) | 0.13 |
| ‒ ppFVC, mean (sd) | 92.9 (20.2) | 88.1 (23.8) | −0.25 (−0.09, 0.78) | 0.49 |
| ‒ FEV1/FVC, mean (sd) | 87.1 (7.9) | 83.9 (8.9) | −0.37 (−0.62, −0.13) | 0.25 |
| Bronchodilator response test, n (%) | 10 (34.5) | 19 (65.5) | ||
| ‒ Positive bronchodilator response test, n (%) | 0 (0) | 11 (57.9) | 0.57 (0.21, 0.92) | 0.001 |
| Reported symptoms | ||||
| ‒ Episodes of dyspnea, n (%) | 4 (10.8) | 18 (64.3) | 0.55 (0.36, 0.70) | <0.001 |
| ‒ Wheezing, n (%) | 8 (21.6) | 15 (53.6) | 0.33 (0.09, 0.53) | 0.31 |
| Modified Bhalla score, mean (sd) | 4.1 (2.4) | 3.6 (2.3) | 0.21 (0.08, 0.42) | 0.25 |
| Mosaic pattern on HRCT, n (%) | 12 (32.4) | 24 (85.7) | 0.53 (0.33, 0.68) | <0.001 |
| Exacerbations during the first six months of treatment, median (IQR) | 2 (1,2) | 2 (1,3) | 0.13 (0.02, 0.28) | 0.27 |
ICS: Inhaled corticosteroids; HRCT: High-resolution computed tomography; SPT: Skin prick tests; pp: percent predicted.